Post Profile

Long-term experience supports efficacy and safety of PRRT for treating neuroendocrine tumors

(Mary Ann Liebert, Inc./Genetic Engineering News) More than 10 years of published clinical data and personal experience using PRRT-based targeted therapy of neuroendocrine tumors supports the effectiveness of this novel treatment approach and the ability to minimize and manage potential toxic side effects. A comprehensive review of somatostatin analog peptide receptor radionuclide therapy is published in Cancer Biotherapy and Radiopharmaceuticals.
read more


Related Posts

Study shows functional effects of human stem cell delivery to heart muscle after heart attack

Health : EurekAlert: Health

(Mary Ann Liebert, Inc./Genetic Engineering News) Researchers delivered human stem cells seeded in biological sutures to the damaged heart muscles of rats following induced acute myocardial infarction and assessed the effects on car...

Radionuclide Therapy For Neuroendocrine Tumors Shows Improvement In Quality Of Life And Reduction Of Tumor Size

Health : Medical News Today

According to new Dutch research featured in the September issue of The Journal of Nuclear Medicine, a peptide receptor radiolabeled therapy (PRRT), [177Lu-DOTA0,Tyr3]Octreotate (177Lu-octreotate), is effective not only in decreasing...

'Gene therapy in a box' effective, reports Nature Communications

Health : EurekAlert: Health

(Fred Hutchinson Cancer Research Center) A table-top device that enables medical staff to genetically manipulate a patient's blood to deliver potential new therapies for cancer, HIV and other diseases would eliminate the need for mu...

Patients With Tumors In Nerve- And Hormone-Sensitive Organs Live Years Longer Following Targeted Peptide Receptor Radionuclide Therapy

Health : Medical News Today

Peptide-receptor radionuclide therapy (PRRT) has been a subject of growing research on neuroendocrine tumors, which take up residence in a variety of organs replete with nerve cells that respond to hormone signaling. A countrywide s...

Safety data support human testing of hematopoietic stem cell gene therapy for mucopolysaccharid I

Health : EurekAlert: Health

(Mary Ann Liebert, Inc./Genetic Engineering News) Extensive biosafety studies of hematopoietic stem cell (HSC) gene therapy, intended to replace a protein that patients with the inherited disease mucopolysaccaridosis I (MPS I) canno...


Copyright © 2016 Regator, LLC